Durable Immunotherapy Benefits Foster Excitement in Bladder Cancer, Despite Low Response Rates – Targeted Oncology
Targeted Oncology |
Durable Immunotherapy Benefits Foster Excitement in Bladder Cancer, Despite Low Response Rates
Targeted Oncology While immunotherapy agents have only demonstrated a clinical benefit for approximately 15% to 20% of patients with urothelial carcinoma, it's the durable responses observed in these patients that have doctors excited, says Arlene Siefker-Radtke, MD. |
